Float Like A Butterfly: Agility In Biotech

This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC.  

In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations.  This blog builds upon comparisons with tech relating to business model, investment returns and the dynamics of the different VC ecosystems.  In this post, I would like to draw lessons from how tech startups actually work and organize themselves.

One of the most dominant themes in tech is Agile software development, an approach that has been adopted by all of the most successful startups around the world.  Agile involves creating a simplified piece of software that is then iterated rapidly through input from real customers.  Iterations are generally short – typically one to four weeks – and are aptly called ‘sprints’.

On its

Continue reading "Float Like A Butterfly: Agility In Biotech"

Allostery: Realizing The Promise

This blog was written by Jonathan Montagu, CEO of Hotspot Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC.

It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and loss of appetite.  A physical exam reveals a grossly enlarged spleen while basic blood work uncovers white blood cell counts between thirty and sixty times normal levels.

Historically, patients with CML would live only three to five years, during which time the disease would quickly transform from a chronic leukemia to an aggressive and fatal acute leukemia.  Thankfully, CML became the poster child for targeted cancer therapy, as molecules designed to specifically target the ATP-binding active site of Abl1 led to approval of imatinib Gleevec® in 2001.  CML patients now enjoy roughly 84% ten-year survival.  With peak sales of $4.6B, Gleevec was so successful

Continue reading "Allostery: Realizing The Promise"